AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAYNE PHARMA GROUP LTD

7.225

-0.005-0.07%

Volume:642.45K

Turnover:4.65M

Market Cap:587.00M

PE:-4.41

High:7.240

Open:7.230

Low:7.220

Close:7.230

Loading ...

Overview Company News Filings

Small companies, big swings and four future leaders that stand out

Wilsons Downgrades Mayne Pharma Group to Market-Weight from Overweight, Price Target is AU$7.40

MT Newswires Live

Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ...

Mayne Pharma Group Posts Narrower Fiscal H1 Loss, Higher Revenue

MT Newswires Live

BRIEF-Mayne Pharma Posts H1 Gross Margin 53%

Mayne Pharma Group - Company Expects to Grow Underlying Ebitda in 2Hfy25 via Revenue Growth

THOMSON REUTERS

Mayne Pharma H1 Revenue AUD 94.3 Million

THOMSON REUTERS

Mayne Pharma H1 Gross Margin 53%

THOMSON REUTERS

Australian Shares Slide Despite Tech Stocks Rally; Mayne Pharma to be Acquired by Cosette in AU$672 Million Deal

MT Newswires Live

Mayne Pharma board backs $672 million takeover bid from Cosette Pharma

Mayne Pharma board backs $672m takeover offer from US giant Cosette

Business News Australia

Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%

Simply Wall St.

ASX Market Close: Index inches lower as investors digest Trump’s tariff plans | February 10, 2025

The Market Herald

Mayne Pharma forecasts up to $215m revenue for 1H25 as growth momentum continues

BRIEF-Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 Million

Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MYX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":7.225,"timestamp":1741148411145,"preClose":7.23,"halted":0,"volume":642451,"delay":0,"changeRate":-0.000692,"change":-0.005,"floatShares":60876799,"shares":81245827,"eps":-1.638289,"lyrEps":-2.188306,"pbRate":1.32,"amount":4645740,"amplitude":0.002766,"volumeRatio":1.060715,"dividePrice":0,"prevYearClose":4.97,"fiveDayClose":7.23,"twentyDayClose":4.6},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":60876799,"roa":"-0.50%","roe":"-23.75%","lyrEps":-2.188306,"volumeRatio":1.060715,"shares":81245827,"dividePrice":0,"high":7.24,"amplitude":0.002766,"preClose":7.23,"low":7.22,"week52Low":3.74,"pbRate":"1.32","psRate":"1.42","week52High":7.46,"institutionHeld":0,"latestPrice":7.225,"committee":0.969722,"eps":-1.638289,"divideRate":0,"volume":642451,"delay":0,"ttmEps":-1.638289,"open":7.23,"prevYearClose":4.97,"prevWeekClose":7.22,"prevMonthClose":7.22,"prevQuarterClose":4.97,"fiveDayClose":7.23,"twentyDayClose":4.6,"sixtyDayClose":5.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null},{"date":"2024-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708902000000,"name":null,"time":"","dateTimestamp":1708866000000,"actualEps":null},{"date":"2023-08-31","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693440000000,"name":null,"time":"","dateTimestamp":1693404000000,"actualEps":null},{"date":"2023-02-28","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677538800000,"name":null,"time":"","dateTimestamp":1677502800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514831397","title":"Small companies, big swings and four future leaders that stand out","url":"https://stock-news.laohu8.com/highlight/detail?id=2514831397","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514831397?lang=en_us&edition=fundamental","pubTime":"2025-02-28 13:12","pubTimestamp":1740719546,"startTime":"0","endTime":"0","summary":"In our reporting season update, I talk to Jason Guthrie about another volatile reporting season in the small to mid-cap end of the ASX. As always there have been many winners and losers and I discuss the trends we are seeing, including margin pressures and a reckoning for some of the best performing companies and sectors of recent months. I also outline the performance of a some of IML’s key holdings including Mayne Pharma , oOh!Media , Integral Diagnostics  and Light & Wonder .So, it’s been very volatile, but I think if we look at the reporting season in totality, the key messages we can take away are that consumers are still fairly price-conscious and value-conscious, but it’s not diabolical in terms of how the consumer is performing. If you look at the revenue lines that many of the companies have reported this reporting season, that’s actually held up OK. Companies are growing their top line o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/small-companies-big-swings-and-four-future-leaders-that-stand-out","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/small-companies-big-swings-and-four-future-leaders-that-stand-out","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["SWM.AU","BK7052","IDX.AU","BK7124","LNW.AU","MYX.AU","OML.AU","BK7078","BK7508","BK7096","BK7045"],"gpt_icon":0},{"id":"2514873529","title":"Wilsons Downgrades Mayne Pharma Group to Market-Weight from Overweight, Price Target is AU$7.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2514873529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514873529?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:22","pubTimestamp":1740648162,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group (ASX:MYX) has an average rating of outperform and price targets ranging from AU$5.95 to AU$7.40, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU"],"gpt_icon":0},{"id":"2514886705","title":"Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514886705","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514886705?lang=en_us&edition=fundamental","pubTime":"2025-02-26 17:00","pubTimestamp":1740560431,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Revenues increased by 13% to $213.1 million, driven by strong growth in the women's health segment.Gross margin expanded significantly to 61.4% from 56.3% in the prior corresponding period.Underlying EBITA rose by 288%, showcasing substantial improvement in profitability.Positive operating cash flow of $25.9 million from continued operations, a significant turnaround from a negative cash flow in the previous period.The women's health portfolio showed strong performance with revenues up 30% and direct contribution up 117%.Revenue from dermatology showed only modest growth of 1%, with competition affecting sales of certain products.International segment's direct contribution declined due to timing effects of shipments and production schedules.Despite improvements, the company faces ongoing challenges with legacy inventory returns affecting revenue in the women's health segment.A:  The turn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mayne-pharma-group-ltd-maynf-090031789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["MYX.AU","MAYNF"],"gpt_icon":0},{"id":"2514020769","title":"Mayne Pharma Group Posts Narrower Fiscal H1 Loss, Higher Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020769?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:06","pubTimestamp":1740535587,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  reported Wednesday a fiscal first-half loss of AU$0.323 per diluted share, narrowing from AU$0.878 per diluted share a year earlier.Revenue for the six months ended Dec. 31, 2024, was AU$213.1 million, up 13% from AU$187.9 million a year earlier.The company said it expects to grow underlying earnings before interest, taxes, depreciation, and amortization in the second fiscal half via revenue growth and cost leverage.The firm did not declare a dividend for the reported half-year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU"],"gpt_icon":0},{"id":"2514022114","title":"BRIEF-Mayne Pharma Posts H1 Gross Margin 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022114?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:30","pubTimestamp":1740533428,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Posts H1 Gross Margin 53%Feb 26  - Mayne Pharma Group Ltd MYX.AX:H1 GROSS MARGIN 53%H1 REVENUE AUD 94.3 MILLIONH1 GROSS PROFIT AUD 76.9 MILLIONH1 ADJUSTED EBITDA AUD 31 MILLIONCOMPANY EXPECTS TO GROW UNDERLYING EBITDA IN 2HFY25 VIA REVENUE GROWTHFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX92B737:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2514408042","title":"Mayne Pharma Group - Company Expects to Grow Underlying Ebitda in 2Hfy25 via Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2514408042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514408042?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2514042109","title":"Mayne Pharma H1 Revenue AUD 94.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042109?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2514004217","title":"Mayne Pharma H1 Gross Margin 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514004217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514004217?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:54","pubTimestamp":1740520494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX92B737:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2513239035","title":"Australian Shares Slide Despite Tech Stocks Rally; Mayne Pharma to be Acquired by Cosette in AU$672 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2513239035","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513239035?lang=en_us&edition=fundamental","pubTime":"2025-02-21 14:17","pubTimestamp":1740118679,"startTime":"0","endTime":"0","summary":"Australian shares slid on Friday's close despite gains from Asian markets fuelled by the rise in tech stocks as Chinese tech firm Alibaba Group Holdings' revenue beat estimates.The S&P/ASX 200 Index f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7002","XKO.AU","RBA","LU1303367103.USD","XJO.AU","BK4137","DHG.AU","BK7508","BK7034","LU1815336091.USD","LU0757428866.USD","QBE.AU","XAO.AU","LU2098885051.SGD","BK7503","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2513378235","title":"Mayne Pharma board backs $672 million takeover bid from Cosette Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2513378235","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513378235?lang=en_us&edition=fundamental","pubTime":"2025-02-21 10:08","pubTimestamp":1740103689,"startTime":"0","endTime":"0","summary":"Mayne Pharma  has received a takeover offer at a price of $7.40 per share from US-based pharmaceutical company Cosette Pharma, valuing the company at $672 million.Cosette has a portfolio of products in women’s health and dermatology and a long history of manufacturing complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories.The US-based firm is backed by healthcare-focused private equity firm Avista Healthcare Partners and funds controlled by private markets investment management firm Hamilton Lane.Mayne Pharma chief executive officer Shawn Patrick O’Brien said this was a pivotal moment in Mayne’s journey to improve patient access to life-enhancing medications.“Attracting an offer from a strategic buyer who is active in the US dermatology and women’s health markets, such as Cosette, reflects the excellent work our teams have been doing to strengthen our company over the last year and more,” chair Frank Condella added.The Mayne Pharma board has ","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-Cosette-Pharmaceuticals-takeover-bid.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-Cosette-Pharmaceuticals-takeover-bid.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mayne-pharma-board-backs-takeover-bid-cosette/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2513710233","title":"Mayne Pharma board backs $672m takeover offer from US giant Cosette","url":"https://stock-news.laohu8.com/highlight/detail?id=2513710233","media":"Business News Australia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513710233?lang=en_us&edition=fundamental","pubTime":"2025-02-21 00:00","pubTimestamp":1740067200,"startTime":"0","endTime":"0","summary":"The board of Adelaide-based Mayne Pharma (ASX: MYX) has thrown its ...","market":null,"thumbnail":"https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67b7c14486236.jpg?v=2&m=37caf18f1cfc79cb642c7453e89f30a7&lqip(10)","type":0,"news_type":0,"thumbnails":["https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67b7c14486236.jpg?v=2&m=37caf18f1cfc79cb642c7453e89f30a7&lqip(10)"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businessnewsaustralia.com/articles/mayne-pharma-board-backs--672m-takeover-offer-from-us-giant-cosette.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"businessau_stock","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2511156145","title":"Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511156145","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511156145?lang=en_us&edition=fundamental","pubTime":"2025-02-13 09:33","pubTimestamp":1739410405,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Limited ( ASX:MYX ) shareholders would be excited to see that the share price has had a great month...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/mayne-pharma-group-limited-asxmyx-held-back-by-insufficient","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2510881995","title":"ASX Market Close: Index inches lower as investors digest Trump’s tariff plans | February 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510881995","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510881995?lang=en_us&edition=fundamental","pubTime":"2025-02-10 14:28","pubTimestamp":1739168880,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.34% at 8,482 points.Investment manager Franklin Templeton says President Trump’s latest trade tariffs threat could be a “strategic negotiating tool or the beginning of a prolonged trade war”. In a client note the company raised the prospect the move would escalate tensions with key US trade partners and heighten the risk of a full-scale trade war.Staples was the best performing sector, up 0.5%, followed by Utilities, up 0.45%. IT was the biggest loser, down 1.4%, followed by Telecommunication, down 1.1%, and Materials, down 0.7%.BlueScope Steel  closed up 1.8% on revelations it will emerge a winner if US President Donald Trump imposes 25% tariffs on all imports of steel and aluminium into the US. BlueScope is one of the biggest steelmakers in the US.Star Entertainment  closed up 13.6% after the casino operator confirmed it hadreceived bids to buy out its stake in Brisbane’s Queen’s Wharf development. Meanwhile, corporate regulatorASIC’s case against former Star","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-inches-lower-as-investors-digest-trumps-tariff-plans-february-10-2025-2025-02-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BSL.AU","BK7503","BK7096","BK7129","CAR.AU","BK7078","BK7104","POL.AU","SGR.AU","MYX.AU","BK7508","WTC.AU","BK7002","BK7016"],"gpt_icon":0},{"id":"2510000363","title":"Mayne Pharma forecasts up to $215m revenue for 1H25 as growth momentum continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2510000363","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510000363?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:48","pubTimestamp":1739152098,"startTime":"0","endTime":"0","summary":"Mayne Pharma  has reported a forecast revenue of between $210 million and $215m for the first half of the 2025 financial year, reflecting growth of approximately 14% on the previous corresponding period .The company is also expecting to report underlying EBITDA of between $30m and $32m, representing an increase of almost 300% on the pcp.The underlying EBITDA will be driven by continued growth across Mayne’s Women’s Health portfolio, with increased operating leverage and improved margins in its Dermatology product sales.“We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded, particularly within our Women’s Health segment,” he said.“[We] believe our portfolio of branded medicines within Women’s Health and Dermatology, coupled with the leverage we can generate through our existing infrastructure and efficiencies, will deliver improvements in our financial and operating metrics.”","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-December-2024-half-yearly-market-update.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Mayne-Pharma-ASX-MYX-December-2024-half-yearly-market-update.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mayne-pharma-forecasts-revenue-1h25-growth-momentum-continues/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2510107286","title":"BRIEF-Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2510107286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510107286?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:29","pubTimestamp":1739150986,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 MillionFeb 10  - Mayne Pharma Group Ltd MYX.AX:EXPECTS 1H FY25 REVENUES TO BE A$210 - A$215 MILLIONSEES 1H FY25 UNDERLYING EBITDA1 OF A$30 - A$32 MILLIONFurther company coverage: MYX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P002U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU"],"gpt_icon":0},{"id":"2510562077","title":"Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2510562077","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510562077?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:13","pubTimestamp":1739150016,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) is having a underwhelming start to the week. In afternoon trade, the benchmark index is down 0.3% to 8,488.7 points. Four ASX shares that are not letting that hold the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/10/why-ansell-gqg-mayne-pharma-and-star-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["EBIT","MYX.AU","BK7501","SGR.AU","BK7508","XJO.AU","BK7126","GQG.AU","BK4585","ANN.AU","BK7078","BK7096","DBC","BK7062","BK4588"],"gpt_icon":1}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":41}]}}